Home Cart Sign in  
Chemical Structure| 17334-08-6 Chemical Structure| 17334-08-6

Structure of 17334-08-6

Chemical Structure| 17334-08-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 17334-08-6 ]

CAS No. :17334-08-6
Formula : C5H8N2O
M.W : 112.13
SMILES Code : OCC1=NC=CN1C
MDL No. :MFCD00964673
InChI Key :CDQDMLWGTVLQEE-UHFFFAOYSA-N
Pubchem ID :573612

Safety of [ 17334-08-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 17334-08-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 8
Num. arom. heavy atoms 5
Fraction Csp3 0.4
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 29.62
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

38.05 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

-0.74
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-0.84
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-0.24
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.94
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.19
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-0.51

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.4
Solubility 44.4 mg/ml ; 0.396 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

0.52
Solubility 373.0 mg/ml ; 3.32 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.57
Solubility 30.4 mg/ml ; 0.271 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.58 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.41

Application In Synthesis of [ 17334-08-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 17334-08-6 ]

[ 17334-08-6 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 17334-08-6 ]
  • [ 78667-04-6 ]
YieldReaction ConditionsOperation in experiment
95% With thionyl chloride In diethyl ether; 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran Synthesis of 2-(Chloromethyl)-1-methyl-1H-imidazole Hydrochloride (BB7)
To a solution of (BB6) (35.5 g, 316.96 mmol) in DCM (1500 mL) was added SOCl2 (330 mL, 4436 mmol) at 0° C.
The reaction was warmed to ambient temperature and stirred for 5 h.
The reaction mixture was concentrated, the residue was washed with DCM (2*500 mL), followed by Et2O (2*200 mL) to obtain (BB7) (50 g, 95percent) as an off-white solid. Rf: 0.4 (EtOAc).
1H NMR (400 MHz, DMSO-d6): δ 7.76 (1H, app d), 7.70 (1H, app d), 5.17 (2H, s), 3.87 (3H, s); ink 131 (MH)+.
88% Cooling with ice; Reflux 1-Methyl-2-hydroxymethyl imidazole (15.0 g, 134 mmol) was added, with shaking and exclusion of moisture, over a period of 15 min to ice cooled thionyl dichloride (24.6 mL, 30 g, 0.25 mol). The reactants were then heated under reflux for 15 min. The cooled solution was evaporated under reduced pressure followed by recrystallization from ethanol (25 mL) and dried under high vacuum to give 2-(chloromethy1)-1-methyl-1H-imidazole hydrochloride as brown crystals. Yield: 15.1g, 88percent. 1H NMR (CDCl3) δ ppm: 7.79 (s, 1H), 7.70 (s, 1H), 5.2 (s, 2H), 3.86 (s, 3H). 3C NMR (CD3OD) δ ppm: 142.05, 124.7, 119.08, 33.9, 31.4. TOF-MS m/z: 131.0384 (M+H+, 100percent). Molecular formula of cation, C5H7N2Cl, calculated m/z of cation: 131.04 (M+H+)
78%
Stage #1: at 0℃; for 0.5 h; Reflux; Inert atmosphere
Stage #2: With hydrogenchloride In water
This compound was synthesised using a modified procedure described in literature.6 1-Methyl-2-hydroxymethyl imidazole (6.500 g, 58.000 mmol) was added in small portions to SOCl2 (12.7 mL, 174 mol) at 0 °C. The mixture was heated under reflux for 30 min. After cooling, the solution was concentrated under reduced pressure followed by recrystallization from ethanol (17 mL) to afford 2-(chloromethy1)-1-methyl-1H-imidazole hydrochloride. Yellow crystals; 7.580g, yield: 78percent. The NMR spectrum was according to literature.6 1H NMR (CDCl3) δ = 7.79 (d, 1H, J = 1.9 Hz; ImH), 7.70 (d, 1H, J = 1.9 Hz; ImH), 5.20 (s, 2H; CH2Cl), 3.86 ppm (s, 3H; NCH3).
References: [1] Patent: US2012/322722, 2012, A1, .
[2] Tetrahedron Letters, 2011, vol. 52, # 41, p. 5308 - 5310.
[3] Tetrahedron, 1996, vol. 52, # 48, p. 15171 - 15188.
[4] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1993, # 19, p. 2291 - 2302.
[5] Tetrahedron Letters, 2013, vol. 54, # 45, p. 6087 - 6089.
[6] Organic and Biomolecular Chemistry, 2009, vol. 7, # 2, p. 229 - 231.
[7] Patent: US6646122, 2003, B1, . Location in patent: Page/Page column 10.
[8] Patent: EP1422228, 2004, A1, . Location in patent: Page 228.
[9] Patent: EP1724263, 2006, A1, . Location in patent: Page/Page column 29.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 17334-08-6 ]

Alcohols

Chemical Structure| 3724-26-3

A207173 [3724-26-3]

(1H-Imidazol-2-yl)methanol

Similarity: 0.90

Chemical Structure| 334893-99-1

A118970 [334893-99-1]

(5-Chloro-1-methyl-1H-imidazol-2-yl)methanol

Similarity: 0.81

Chemical Structure| 1615-14-1

A356029 [1615-14-1]

2-(1H-Imidazol-1-yl)ethanol

Similarity: 0.77

Chemical Structure| 34793-28-7

A332832 [34793-28-7]

3-(1H-Imidazol-1-yl)propane-1,2-diol

Similarity: 0.69

Chemical Structure| 1100750-16-0

A207896 [1100750-16-0]

5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-6-ol

Similarity: 0.68